These findings set the stage for testing empagliflozin, an inhibitor of the kidney sodium glucose cotransporter 2 (SGLT2), which also lowers serum 1,5AG6P in GSD‐Ib patients. The gene discussed is SLC5A2; the disease is disorder of glycogen metabolism.